Home
NewsNewsThe MOAA-Endorsed Bill for Fertility Challenges seeks to expand fertility care access for veterans by recognising infertility as a service-connected condition. By reducing barriers to IVF and treatment, the legislation addresses toxic exposure risks and aims to provide timely, equitable reproductive healthcare support for those who served.
A significant bipartisan effort is underway to address the long-term reproductive health of the nation's veterans. Introduced on March 5, 2026, the MOAA-Endorsed Bill for Fertility Challenges, officially known as the Warrior Infertility Act (H.R. 7841), seeks to expand access to critical fertility care for veterans whose reproductive health may have been compromised by toxic exposures during their military service.
Led by Representative Kelly Morrison (D-Minn.) and co-led by Representative Jay Obernolte (R-Calif.), the legislation aims to classify infertility as a presumptive condition under the Sergeant First Class Heath Robinson Honouring Our Promise to Address Comprehensive Toxics (PACT) Act. By establishing this presumption, the bill would remove the "burdensome hurdles" veterans currently face when trying to prove a direct link between their infertility and their time in uniform. Currently, securing coverage for advanced treatments like in vitro fertilisation (IVF) can take months or even years, often due to the lack of an established presumptive connection.
The Military Officers Association of America (MOAA) has been a vocal proponent of this change. Lt Gen. Brian T. Kelly, USAF (Ret), president and CEO of MOAA, emphasised the necessity of this support: “The risks taken by those in uniform last far longer than their time in service. The Warrior Infertility Act recognises one of these risks — how exposure to toxins can create problems for those looking to build a family. MOAA thanks Reps. Morrison and Obernolte for this commonsense legislation that will allow these warriors to receive the support and care they've earned ”.
The MOAA-Endorsed Bill for Fertility Challenges is backed by a growing body of research highlighting the occupational hazards of military life. Studies indicate that active-duty women experience fertility issues at significantly higher rates than their civilian counterparts. Representative Morrison, a practising OB-GYN for over two decades, stressed that it is the nation's duty to support these service members upon their return.
“When service members put their lives on the line for our country, it's our duty to make sure they're supported when they come home. That includes essential and life-changing reproductive health care,” Morrison stated. “Service members are more likely to struggle with infertility but still face burdensome hurdles to getting treatment. Recognizing infertility as a service-connected condition will help ensure veterans do not fall through the cracks ”.
Representative Obernolte echoed these sentiments, noting that the MOAA-Endorsed Bill for Fertility Challenges is designed to remove "unnecessary barriers" that prevent veterans from building families after their service. The legislation has garnered a wide coalition of support, including the American Legion, the Elizabeth Dole Foundation, and the National Military Family Association. If enacted, the act would mark a major milestone in recognising the full scope of health challenges tied to toxic exposure and ensure veterans receive the family-building care they deserve.
A groundbreaking Nature Medicine study compares AI deep learning against expert embryologists in selecting embryos. While pregnancy rates remain comparable, the study uncovers a massive advantage in efficiency that could revolutionize IVF labs worldwide. Discover how AI-driven embryo selection accuracy is reshaping the future of fertility treatment.
FertilAI has received EU MDR clearance for tools advancing Predictive AI in Fertility through its Fertilane platform. StimAI and OvuPredict help clinicians optimise IVF timing, predict ovulation and improve scheduling efficiency. The technology supports scalable fertility care, reduced monitoring needs and better patient treatment experiences globally.
The Ferring Global Fertility Monitor has been launched by Ferring Pharmaceuticals and Gallup to examine fertility trends in 70 countries. Through large-scale surveys, the project will explore economic, social, and cultural influences on parenthood decisions. Insights are expected to guide policy, healthcare planning, and future demographic strategies.
Maven Clinic has expanded its Fertility and Family Building program with earlier diagnostics, wearable integration, and AI-powered personalised care. The enhanced platform supports faster diagnosis, improved treatment decisions, and condition-specific pathways for PCOS, endometriosis, and oncofertility. The rollout continues through 2026 with added innovations and partnerships.
Germany is debating the legalization of egg donation in Germany, challenging decades-old restrictions under the Embryo Protection Act. Experts argue reform is overdue to align with modern reproductive science, reduce fertility tourism, and improve patient care, while policymakers work to balance ethical concerns with growing demand for advanced fertility treatments.
A new review highlights the link from Forever Chemicals to reduced ART outcomes, showing how PFAS exposure impacts fertility, pregnancy, and reproductive health. The findings raise urgent concerns for IVF patients and call for stronger regulation, deeper research, and systemic action to address environmental risks in reproductive medicine.
The 2027 Title X NOFO introduces a major policy shift toward addressing infertility crisis in the U.S. It mandates basic infertility services, expands male reproductive health focus, and promotes education on body literacy and lifestyle factors, aiming to support family formation alongside traditional contraceptive services.
